MA53503A - Polythérapie faisant appel à des antagonistes de récepteurs 4 de chimiokines c-c (ccr4) et à un ou plusieurs inhibiteurs de points de contrôle immunitaires - Google Patents
Polythérapie faisant appel à des antagonistes de récepteurs 4 de chimiokines c-c (ccr4) et à un ou plusieurs inhibiteurs de points de contrôle immunitairesInfo
- Publication number
- MA53503A MA53503A MA053503A MA53503A MA53503A MA 53503 A MA53503 A MA 53503A MA 053503 A MA053503 A MA 053503A MA 53503 A MA53503 A MA 53503A MA 53503 A MA53503 A MA 53503A
- Authority
- MA
- Morocco
- Prior art keywords
- ccr4
- antagonists
- immune checkpoint
- chemokine receptor
- checkpoint inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724412P | 2018-08-29 | 2018-08-29 | |
| US201862771853P | 2018-11-27 | 2018-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53503A true MA53503A (fr) | 2021-07-07 |
Family
ID=69639506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053503A MA53503A (fr) | 2018-08-29 | 2019-08-28 | Polythérapie faisant appel à des antagonistes de récepteurs 4 de chimiokines c-c (ccr4) et à un ou plusieurs inhibiteurs de points de contrôle immunitaires |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11446289B2 (enExample) |
| EP (1) | EP3843734B1 (enExample) |
| JP (1) | JP7554180B2 (enExample) |
| KR (1) | KR102817790B1 (enExample) |
| CN (1) | CN112601526B (enExample) |
| AU (1) | AU2019327430B2 (enExample) |
| BR (1) | BR112021002928A2 (enExample) |
| CA (1) | CA3109498A1 (enExample) |
| ES (1) | ES3064498T3 (enExample) |
| IL (1) | IL280831B2 (enExample) |
| MA (1) | MA53503A (enExample) |
| MX (1) | MX2021002302A (enExample) |
| SG (1) | SG11202101454PA (enExample) |
| TW (1) | TWI888358B (enExample) |
| WO (1) | WO2020047030A1 (enExample) |
| ZA (1) | ZA202101055B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6141864B2 (ja) | 2011-12-01 | 2017-06-07 | ケモセントリックス，インコーポレイティド | Ｃｃｒ（４）アンタゴニストとしての置換アニリン |
| ES3064498T3 (enExample) * | 2018-08-29 | 2026-04-27 | Chemocentryx Inc | |
| KR20230149729A (ko) * | 2022-04-19 | 2023-10-27 | 케모센트릭스, 인크. | Ccr4 길항제 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US20020173524A1 (en) * | 2000-10-11 | 2002-11-21 | Tularik Inc. | Modulation of CCR4 function |
| AU2003256923A1 (en) | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
| JP2007210887A (ja) | 2004-06-21 | 2007-08-23 | Astellas Pharma Inc | 縮合二環性ピリミジン誘導体 |
| US20090182140A1 (en) | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| JP2009148309A (ja) | 2007-12-18 | 2009-07-09 | Uni Charm Corp | 吸収性物品 |
| US8263073B2 (en) | 2008-02-04 | 2012-09-11 | Medarex, Inc. | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
| JP5523572B2 (ja) | 2009-10-26 | 2014-06-18 | 中国石油化工股▲ふん▼有限公司 | 担持型非メタロセン触媒、その製造方法およびその使用 |
| WO2011050565A1 (zh) | 2009-10-26 | 2011-05-05 | 中国石油化工股份有限公司 | 负载型非茂金属催化剂、其制备方法及其应用 |
| WO2011056423A2 (en) | 2009-10-28 | 2011-05-12 | Exxonmobil Chemical Patents Inc. | Catalyst compounds and use thereof |
| US8952113B2 (en) | 2009-11-13 | 2015-02-10 | China Petroleum & Chemical Corp. | Supported nonmetallocene catalyst, preparation and use thereof |
| EP2500364B1 (en) | 2009-11-13 | 2020-03-04 | China Petroleum & Chemical Corporation | Supported non-metallocene catalyst preparation method and application thereof |
| US20140031547A1 (en) | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
| JP6141864B2 (ja) * | 2011-12-01 | 2017-06-07 | ケモセントリックス，インコーポレイティド | Ｃｃｒ（４）アンタゴニストとしての置換アニリン |
| CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JP7305300B2 (ja) * | 2014-11-05 | 2023-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 併用免疫療法 |
| WO2016181349A1 (en) * | 2015-05-14 | 2016-11-17 | Pfizer Inc. | Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body |
| TW201713332A (zh) * | 2015-07-14 | 2017-04-16 | 協和醱酵麒麟有限公司 | 包含與抗體組合投予之ｉｄｏ抑制物之腫瘤治療劑 |
| TWI724056B (zh) * | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| KR102401963B1 (ko) | 2016-06-27 | 2022-05-25 | 케모센트릭스, 인크. | 면역조절제 화합물 |
| PL3490565T3 (pl) * | 2016-07-29 | 2022-09-26 | Rapt Therapeutics, Inc. | Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| WO2018101448A1 (en) * | 2016-11-30 | 2018-06-07 | Kyowa Hakko Kirin Co., Ltd. | Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody |
| ES3064498T3 (enExample) * | 2018-08-29 | 2026-04-27 | Chemocentryx Inc |
-
2019
- 2019-08-28 ES ES19854176T patent/ES3064498T3/es active Active
- 2019-08-28 US US16/553,339 patent/US11446289B2/en active Active
- 2019-08-28 CN CN201980055588.1A patent/CN112601526B/zh active Active
- 2019-08-28 KR KR1020217008833A patent/KR102817790B1/ko active Active
- 2019-08-28 SG SG11202101454PA patent/SG11202101454PA/en unknown
- 2019-08-28 MA MA053503A patent/MA53503A/fr unknown
- 2019-08-28 JP JP2021510337A patent/JP7554180B2/ja active Active
- 2019-08-28 MX MX2021002302A patent/MX2021002302A/es unknown
- 2019-08-28 AU AU2019327430A patent/AU2019327430B2/en active Active
- 2019-08-28 CA CA3109498A patent/CA3109498A1/en active Pending
- 2019-08-28 EP EP19854176.5A patent/EP3843734B1/en active Active
- 2019-08-28 IL IL280831A patent/IL280831B2/en unknown
- 2019-08-28 WO PCT/US2019/048461 patent/WO2020047030A1/en not_active Ceased
- 2019-08-28 BR BR112021002928-1A patent/BR112021002928A2/pt unknown
- 2019-08-29 TW TW108130967A patent/TWI888358B/zh active
-
2021
- 2021-02-16 ZA ZA2021/01055A patent/ZA202101055B/en unknown
-
2022
- 2022-08-16 US US17/820,179 patent/US12011439B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3109498A1 (en) | 2020-03-05 |
| ZA202101055B (en) | 2025-08-27 |
| NZ773164A (en) | 2025-07-25 |
| US12011439B2 (en) | 2024-06-18 |
| WO2020047030A1 (en) | 2020-03-05 |
| KR20210053306A (ko) | 2021-05-11 |
| EP3843734B1 (en) | 2026-01-28 |
| TWI888358B (zh) | 2025-07-01 |
| US20230097128A1 (en) | 2023-03-30 |
| TW202023555A (zh) | 2020-07-01 |
| MX2021002302A (es) | 2021-04-28 |
| IL280831B2 (en) | 2024-05-01 |
| JP2021536442A (ja) | 2021-12-27 |
| US11446289B2 (en) | 2022-09-20 |
| SG11202101454PA (en) | 2021-03-30 |
| JP7554180B2 (ja) | 2024-09-19 |
| AU2019327430A1 (en) | 2021-03-18 |
| AU2019327430B2 (en) | 2024-10-03 |
| EP3843734C0 (en) | 2026-01-28 |
| EP3843734A1 (en) | 2021-07-07 |
| BR112021002928A2 (pt) | 2021-05-11 |
| IL280831B1 (en) | 2024-01-01 |
| CN112601526B (zh) | 2025-10-03 |
| EP3843734A4 (en) | 2022-05-25 |
| CN112601526A (zh) | 2021-04-02 |
| US20200069673A1 (en) | 2020-03-05 |
| ES3064498T3 (enExample) | 2026-04-27 |
| KR102817790B1 (ko) | 2025-06-05 |
| IL280831A (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3843734A4 (en) | COMBINATION THERAPY USING C-CHEMOCINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS | |
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| IL290479A (en) | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | |
| DK4058445T3 (da) | Glp-1-receptoragonist og anvendelse deraf | |
| IL284223A (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| PT3806955T (pt) | Agonistas dos receptores glp-1 e suas utilizações | |
| IL288479A (en) | Glucagon-like peptide 1 receptor agonists | |
| DK3806855T5 (da) | GLP-1-receptoragonister og anvendelser deraf | |
| HUE058044T2 (hu) | Fenilpirrolidinon-formil peptid 2 receptor agonisták | |
| DK3793586T3 (da) | Opløselige komplementreceptor type 1 (sCR1) varianter og anvendelse deraf | |
| IL283755A (en) | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors, compositions comprising same and uses thereof | |
| DK3707159T3 (da) | Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf | |
| EP3624036C0 (en) | ELECTRONIC DEVICES AND METHODS FOR PREVENTING ENTRY OF AUTHENTICATION CODES IN MULTI-PERSON ENVIRONMENTS | |
| PL4025592T3 (pl) | Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej | |
| FR24C1010I2 (fr) | Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux | |
| CY1125582T1 (el) | Συνθεσεις και μεθοδοι για εκλυση μακρας διαρκειας των ανταγωνιστων της εκλυτικης ορμονης των γοναδοτροπινων (gnrh). | |
| EP3747989A4 (en) | LACTOBACILLUS PLANTARUM CJLP17 WITH ANTIVIRAL AND IMMUNOMODULATING EFFECT AND COMPOSITION THEREOF | |
| IL273188A (en) | Treatment with a combination of chemokine receptor 2 (CCR2) inhibitors and a PD-1/PD-L1 inhibitor | |
| IL284187A (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| IL281769A (en) | Cd40l antagonist and uses thereof | |
| EP3645120A4 (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION | |
| EP3740756A4 (en) | MEANS AND METHOD OF PREDICTING RESPONSE TO THERAPY | |
| EP3996704A4 (en) | MULTIPLE THERAPY INCLUDING GPR119 AGONISTS AND DPP-4 INHIBITORS | |
| MX2017009448A (es) | Proceso para el tratamiento terapeutico del sindrome de intestino irritable con diarrea predominante usando bacillus coagulans sbc37-01, mtcc 5856. |